CJC‑1295 and Ipamorelin are two synthetic peptides that have gained popularity among bodybuilders, athletes, and researchers looking to enhance growth hormone release for therapeutic or performance purposes. Their combined use often aims to maximize the secretion of endogenous growth hormone while minimizing side effects associated with other growth hormone secretagogues. Understanding how these peptides work, their recommended dosages, potential benefits, mechanisms, research applications, and the companies that produce them can help users make informed decisions.
What is CJC‑1295 Ipamorelin?
CJC‑1295 is a long‑acting analog of growth hormone‑releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating the release of growth hormone and subsequently insulin‑like growth factor 1 (IGF‑1). Unlike short‑acting GHRH analogs, CJC‑1295 contains a carrier molecule that protects it from rapid degradation, giving it an extended half‑life of up to two weeks. This allows for less frequent dosing while maintaining steady growth hormone stimulation.
Ipamorelin is a selective growth hormone secretagogue (GHS). It mimics ghrelin by binding to the growth hormone secretagogue receptor (GHSR) on pituitary somatotrophs, causing an increase in growth hormone release. Ipamorelin’s high selectivity means it primarily stimulates growth hormone production without significantly affecting cortisol or prolactin levels, which is a common side effect of other GHS peptides.
Together, CJC‑1295 and Ipamorelin create a synergistic effect: the long‑acting GHRH analog maintains baseline stimulation while the short‑acting GHS triggers acute peaks. This dual mechanism can produce higher overall IGF‑1 levels than either peptide alone.
CJC 1295 and Ipamorelin dosage: benefits, mechanisms, and research applications
Dosage Guidelines
The most common dosing regimen for combined use is:
CJC‑1295 (also known as DAC‑GHRH) – 2 to 3 mg administered subcutaneously once a week. The "DAC" variant contains the drug affinity complex that prolongs activity, allowing weekly injections.
Ipamorelin – 100
